Antibody evasion by the P.1 strain of SARS-CoV-2

Abstract

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7 from the UK (12, 10, and 9 changes in the spike, respectively). All have mutations in the ACE2 binding site, with P.1 and B.1.351 having a virtually identical triplet (E484K, K417N/T, and N501Y), which we show confer similar increased affinity for ACE2. We show that, surprisingly, P.1 is significantly less resistant to naturally acquired or vaccine-induced antibody responses than B.1.351, suggesting that changes outside the receptor-binding domain (RBD) impact neutralization. Monoclonal antibody (mAb) 222 neutralizes all three variants despite interacting with two of the ACE2-binding site mutations. We explain this through structural analysis and use the 222 light chain to largely restore neutralization potency to a major class of public antibodies.

Cited by papers we hold 21

• SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines · 2022
  No notice
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models · 2022
  No notice
• A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus · 2022
  No notice
• SARS-COV-2 Variants: Differences and Potential of Immune Evasion · 2022
  No notice
• Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies · 2022
  No notice
• Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events · 2022
  No notice
• Predicting the mutational drivers of future SARS-CoV-2 variants of concern · 2022
  No notice
• COVID-19 vaccine development: milestones, lessons and prospects · 2022
  No notice
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis · 2022
  No notice
• The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022
  No notice
• SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022
  No notice
• SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape · 2022
  No notice
• Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2 · 2021
  Not checked
• Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine · 2021
  No notice
• Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy · 2021
  No notice
• Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics · 2021
  No notice
• An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease · 2021
  No notice
• Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? · 2021
  No notice
• A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics · 2021
  No notice

and 1 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.